Latest Safety News

SRJ Technologies has made significant strides in its three-year growth plan, securing a $6 million joint venture with a Middle East National Oil Company and raising £1.4 million to fund its regional expansion.

Alterity Therapeutics reports strengthened efficacy signals for ATH434 in Multiple System Atrophy and secures a robust cash position to fuel upcoming Phase 3 trials.

Alpha HPA Limited reports significant progress on its HPA First Project Stage 2 construction and secures $30 million funding, while signing new letters of intent with leading semiconductor OEMs.

Austral Gold’s Q3 report reveals a sharp production drop at Guanaco following a fatal accident, prompting a downward revision of 2025 output and cost hikes, while Casposo’s refurbishment signals a new growth phase.

Argenica Therapeutics reports ARG-007 is safe in acute ischemic stroke patients and shows promising efficacy signals in a high-risk subgroup, paving the way for a focused Phase 2b trial.

SRJ Technologies has landed a US$269,000 contract to supply its BoltEx flange integrity solution to a leading FPSO operator offshore Guyana, marking a strategic foothold in a key offshore energy market.

Acusensus Limited has secured a significant expansion of its contract with Queensland’s Department of Transport and Main Roads, doubling its trailer-based speed enforcement units with a $16.6 million deal set to roll out from late 2025.

PainChek Ltd has achieved a pivotal FDA De Novo clearance for its AI-driven Adult pain assessment app, unlocking the US market and driving its annual recurring revenue to $5.6 million. The company also launched its Infant app, targeting a vast global market of pre-verbal children.

Polymetals Resources Ltd has had its trading suspension lifted following an announcement about a serious safety incident at its Endeavor Mine Site, raising questions about operational impacts and regulatory responses.

Polymetals Resources has reported a fatal underground incident at its Endeavor Mine in NSW, resulting in two deaths and a suspension of operations as investigations proceed.

Percheron Therapeutics reports encouraging phase I clinical results for HMBD-002, confirming safety and early efficacy signals, while gearing up for a multi-arm phase II trial in 2026.

EQ Resources Limited reported a robust Q1 FY2026 with soaring tungsten prices, operational upgrades, and significant capital raises to fuel mine expansions.